PHARMACOKINETICS IN THE RAT OF A PANEL OF IMMUNOTOXINS MADE WITH ABRIN-A CHAIN, RICIN-A CHAIN, GELONIN, AND MOMORDIN
- 1 December 1990
- journal article
- research article
- Vol. 50 (23) , 7519-7526
Abstract
A panel of immunotoxins was constructed by chemically attaching the ribosome-inactivating proteins abrin A chain, ricin A chain, gelonin, and momordin to the monoclonal mouse IgG2a antibody Fib75 by means of a disulfide linkage. All the immunotoxins were toxic in tissue culture to the EJ human bladder carcinoma cell line expressing the antigen recognized by Fib75, inhibiting the incorporation of [3H]leucine by 50% at concentrations between 1 .times. 10-10 M and 8 .times. 10-10 M. The pharmacokinetics of the immunotoxins in the normal Wistar rat was determined following i.v. administration. The concentrations of intact immunotoxin in seurm samples taken at various intervals after injection for up to 24 h were measured by solid-phase enzyme-linked immunosorbent assays specific for each of the four different ribosome-inactivating proteins. The Fib75 immunotoxins were cleared from the circulation with comparable, but not identical, biphasic kinetics best described by a two compartment open pharmacokinetic model. The .alpha.-phase half-lives of the panel, between 0.35 and 0.71 h, were similar. The .beta.-phase half-life of Fib75-abrin A chain, 13.3 h, was significantly longer than the .beta.-phase half-lives of Fib75-ricin A chain, Fib75-gelonin, and Fib75-momordin, between 7.5 and 8.6 h. Fib75-abrin A chain was found to be about 3- to 4-fold more resistant than the other immunotoxins to breakdown by reduction of the disulfide linkage between the A chain and the antibody with glutathione in vitro. This suggests that the longer serum half-life of Fib75-abrin A chain may have been due to greater stability against reduction in vivo. Analysis of serum samples obtained up to 24 h after injection of Fib75-abrin A chain revealed that the chemically intact immunotoxin present in the circulation retained full cytotoxic activity. An abrin A chain immunotoxin made with a different monoclonal mouse IgG2a antibody was also found to be more stable against reduction by glutathione in vitro than an analogous ricin A chain immunotoxin. Thus, abrin A chain may possess unique molecular properties that endow immunotoxins made with this A chain with greater stability in vivo than immunotoxins made with ricin A chain or other ribosome-inactivating proteins.This publication has 28 references indexed in Scilit:
- In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates.Journal of Clinical Investigation, 1986
- Study of the plasma clearance of antibody – ricin‐A‐chain immunotoxinsEuropean Journal of Biochemistry, 1986
- An Immunotoxin Composed of Monoclonal Anti-Thy 1.1 Antibody and a Ribosome-Inactivating Protein From Saponaria officinalis: Potent Antitumor Effects In Vitro and In VivoJNCI Journal of the National Cancer Institute, 1985
- The removal of carbohydrates from ricin with endoglycosidases H, F and D and α-mannosidaseBiochimica et Biophysica Acta (BBA) - General Subjects, 1985
- IMMUNOLOGICAL AND BIOLOGICAL STABILITY OF IMMUNOTOXINS INVIVO AS STUDIED BY THE CLEARANCE OF DISULFIDE-LINKED POKEWEED ANTIVIRAL PROTEIN-ANTIBODY CONJUGATES FROM BLOOD1985
- Delivery of Ricin and Abrin A-Chains to Human Carcinoma Cells in Culture following Covalent Linkage to Monoclonal Antibody LICR-LOND-Fib 75Cancer Drug Delivery, 1984
- Properties of the ribosome-inactivating proteins gelonin, Momordica charantia inhibitor, and dianthinsBiochemical Journal, 1982
- Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A.Journal of Biological Chemistry, 1980
- Inhibition of protein synthesis in vitro by proteins from the seeds of Momordica charantia (bitter pear melon)Biochemical Journal, 1980
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978